Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in relapsed/refractory CLL, mantle cell lymphoma, and T-PLL
ISRCTN34386131Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Mar 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of olaparib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and T-cell prolymphocytic leukemia (T-PLL) (3 arms), sponsored by University of Birmingham. Primary endpoint: Clinical response rate at 16 weeks in ATM-deficient relapsed/refractory CLL. Started Mar 2010; status: completed.
02
Drugs
olaparib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on ISRCTN34386131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN34386131.